BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) Significantly...
DARMSTADT, Germany and NEW YORK, Sept. 11, 2018 /PRNewswire-AsiaNet/ -- Not intended for US, Canada and UK-based media- First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type- Results significant in both PDL1+ and all-comer populations ...
Read more https://view-release/?pr-id=75136